Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Richard Stratton

Psychiatry Charlotte, NC Medical Doctor

NPI 1619402849 CMS profile 9750022

6060 Piedmont Row Dr S Ste 500, Charlotte, NC 28287

Open in the dashboard

General payments

$9,009

490 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Stratton of Charlotte, NC is reported in the CMS Open Payments database as having received $9,009 across 490 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,632 139
2024 General $2,523 121
2023 General $2,751 166
2022 General $1,049 62
2021 General $55 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Stratton
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Richard Stratton were reported at $2,632. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Richard Stratton Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $55 $143 $43–$576 $132
2022 $1,049 $153 $50–$590 $149
2023 $2,751 $170 $56–$651 $160
2024 $2,523 $179 $57–$673 $164
2025 $2,632 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,474 109 payments
  2. Otsuka America Pharmaceutical, Inc. $818 46 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $784 70 payments
  4. ITI, Inc. $718 33 payments
  5. Neurocrine Biosciences, Inc. $546 24 payments
  6. Corium, Inc. $536 27 payments
  7. Lundbeck LLC $486 21 payments
  8. Supernus Pharmaceuticals, Inc. $480 10 payments
  9. Tris Pharma Inc $458 20 payments
  10. Janssen Pharmaceuticals, Inc $401 16 payments
  11. Other $2,309 114 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,977 488 payments
  2. Education $32 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $940 71 payments
  2. TRINTELLIX $784 70 payments
  3. REXULTI Psychiatry $676 38 payments
  4. INGREZZA $546 24 payments
  5. Azstarys $536 27 payments
  6. VRAYLAR Neuroscience $534 38 payments
  7. REXULTI Psychiatry $486 21 payments
  8. CAPLYTA $457 23 payments
  9. Dyanavel XR $434 19 payments
  10. Qelbree $427 8 payments
  11. Other $4,446 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,467

Median for Psychiatry: 574

Drug cost

$189,094

Median for Psychiatry: $27,624

Branded share of claims

28.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 14 $114,292
Vraylar Cariprazine Hcl Brand 22 $31,891
Trintellix Vortioxetine Hydrobromide Brand 25 $14,384
Adzenys Xr-Odt Amphetamine Brand 12 $5,624
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 86 $2,109
Methylphenidate Er Methylphenidate Hcl Brand 27 $2,042
Clonazepam Generic 102 $1,519
Duloxetine Hcl Generic 60 $1,427
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 17 $1,159
Bupropion Xl Bupropion Hcl Brand 85 $1,070

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$16,582

Medicare's payments for the services billed

Medicare patients

24

Average age 64

Services billed

239

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Depression 63%
Arthritis 58%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $449
$449 22 —
Qelbree
  • Supernus Pharmaceuticals, Inc. $342
$342 — —
REXULTI
  • Lundbeck LLC $226
  • Otsuka America Pharmaceutical, Inc. $70
$297 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $247
$247 25 —
Azstarys
  • Corium, Inc. $220
$220 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

490 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record